

# Impact of Contrast-Induced Nephropathy on Long-Term Renal Function after Coronary Angiography and Contrast-Enhanced Computed Tomography

Hidekazu Moriya (✉ [h\\_moriya@shonankamakura.or.jp](mailto:h_moriya@shonankamakura.or.jp))

Shonan Kamakura General Hospital

**Yasuhiro Mochida**

Shonan Kamakura General Hospital

**Kunihiro Ishioka**

Shonan Kamakura General Hospital

**Machiko Oka**

Shonan Kamakura General Hospital

**Kyoko Maesato**

Shonan Kamakura General Hospital

**Mizuki Yamano**

Shonan Kamakura General Hospital

**Hiroyuki Suzuki**

Shonan Kamakura General Hospital

**Takayasu Ohtake**

Shonan Kamakura General Hospital

**Sumi Hidaka**

Shonan Kamakura General Hospital

**Shuzo Kobayashi**

Shonan Kamakura General Hospital

---

## Research Article

**Keywords:** contrast media, contrast-induced nephropathy, prognosis, chronic kidney disease

**Posted Date:** January 24th, 2022

**DOI:** <https://doi.org/10.21203/rs.3.rs-1223161/v1>

**License:**  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

---

1 **Impact of contrast-induced nephropathy on long-term renal**  
2 **function after coronary angiography and contrast-enhanced**  
3 **computed tomography**

4

5 Running head: CIN and long-term renal function in CAG/CECT

6

7 Hidekazu Moriya<sup>1)</sup>, Yasuhiro Mochida<sup>1)</sup>, Kunihiro Ishioka<sup>1)</sup>, Machiko Oka<sup>1)</sup>, Kyoko  
8 Maesato<sup>1)</sup>, Mizuki Yamano<sup>1)</sup>, Hiroyuki Suzuki<sup>1)</sup>, Takayasu Ohtake<sup>1)</sup>, Sumi Hidaka<sup>1)</sup>,  
9 and Shuzo Kobayashi<sup>1)</sup>

10

11 Kidney Disease and Transplant Center, Shonan Kamakura General Hospital,  
12 Kanagawa, Japan<sup>1)</sup>

13

14

15 Corresponding author:

16 Hidekazu Moriya

17 Email: [h\\_moriya@shonankamakura.or.jp](mailto:h_moriya@shonankamakura.or.jp)

18 Tel: +81-467-46-1717 Fax: +81-467-45-9792

19 Address: Kidney Disease and Transplant Center, Shonan Kamakura General  
20 Hospital, 1370-1 Okamoto, Kamakura, Kanagawa, Japan 247-8533

21

22 Key Word: contrast media, contrast-induced nephropathy, prognosis, chronic kidney  
23 disease

24

## 1 **Abstract**

### 2 **Background**

3 It remains unclear whether contrast-induced nephropathy (CIN) has a prognostic  
4 impact on subsequent renal dysfunction and whether deteriorating renal function is a  
5 risk factor for CIN. This study aimed to evaluate the occurrence of CIN in patients  
6 with pre-existing renal dysfunction and investigate the long-term effects of worsening  
7 renal function after coronary angiography or contrast-enhanced computed  
8 tomography (CT). The prognostic factors of worsening renal dysfunction were also  
9 analyzed.

### 10 **Methods**

11 This was a prospective cohort study of patients at risk for CIN, defined as an  
12 estimated glomerular filtration rate (eGFR)  $<60$  mL/min/1.73 m<sup>2</sup> on coronary  
13 angiography or eGFR  $<45$  mL/min/1.73 m<sup>2</sup> on contrast-enhanced CT. Serum  
14 creatinine levels and the 2-year prognosis were evaluated. CIN was defined as an  
15 increase in serum creatinine level by more than 0.5 mg/dL or a 25% increase from  
16 the previous value within 72 hours after contrast administration. The primary endpoint

1 was the proportion of patients who had serum Cr doubling or induction of dialysis  
2 within 2 years according to CIN occurrence.

### 3 **Results**

4 Of the 410 patients, 19 patients developed CIN (8/142 patients on coronary  
5 angiography and 11/268 patients on contrast-enhanced CT), and 38 patients had  
6 worsened renal function (21/142 patients on coronary angiography and 17/268  
7 patients on contrast-enhanced CT). CIN was not associated with worsening renal  
8 function at 2 years. Analysis by renal function at the time of coronary angiography or  
9 contrast-enhanced CT (i.e.,  $eGFR \geq 30 \text{ ml/min/1.73 m}^2$  and  $eGFR \leq 1.73 \text{ m}^2$ ) found no  
10 between-group difference in the occurrence of CIN.

### 11 **Conclusions**

12 CIN is not a prognostic risk factor for the long-term of chronic kidney disease after  
13 coronary angiography or contrast-enhanced CT. Pre-existing renal dysfunction is  
14 also not a risk factor for CIN, even if the  $eGFR$  is  $<30 \text{ ml/min/1.73 m}^2$ .

15

## 1 **Introduction**

2 The use of contrast media increases the risk of worsened renal function in patients  
3 with pre-existing renal dysfunction. An estimated glomerular filtration rate (eGFR)  
4 <60mL/min/1.73 m<sup>2</sup> on coronary angiography eGFR <30 mL/min/1.73 m<sup>2</sup> on  
5 transvenous contrast-enhanced CT is associated with the risk of contrast-induced  
6 nephropathy (CIN). However, data on worsening renal function as a long-term  
7 prognosis of CIN are limited. The risk of acute kidney injury after contrast media  
8 administration is also influenced by patient- and procedure-related factors. Clinical  
9 factors that increase the risk for CIN include pre-existing renal dysfunction, diabetes  
10 mellitus in the setting of underlying renal impairment, advanced congestive heart  
11 failure, intravascular volume depletion, administration of large volumes of contrast  
12 media, and the use of high-osmolar contrast media [1-5].

13 In 2018, the Japanese Society of Nephrology, the Japanese Society of Radiology,  
14 and the Japanese Society of Cardiology jointly developed the “Guideline on the use  
15 of iodinated contrast media in patients with kidney disease” [6]. The guidelines  
16 include the definition of CIN, patient assessment, and the occurrence of CIN on

1 coronary angiography and contrast-enhanced CT. The guidelines are aimed to  
2 prevent the occurrence of contrast media-induced renal dysfunction, standardize  
3 renal function assessment methods for patients who use contrast media, and  
4 optimize the use of contrast media. However, the guidelines do not clearly state the  
5 standardization of renal function assessment after contrast testing, evaluation of  
6 long-term effects on renal function, and differentiation from other complications that  
7 affect renal function, such as cholesterol crystal embolism. The impact of contrast  
8 tests on renal function is important for patients with chronic kidney disease. As such,  
9 the long-term decline in renal function and development of other complications due to  
10 contrast tests should be carefully considered.

11 This study aimed to evaluate the occurrence of CIN in patients with renal dysfunction  
12 who underwent contrast media test and treatment (coronary angiography or contrast-  
13 enhanced CT) and the long-term effects of contrast media testing on renal function  
14 after. Further, we examined the prognostic factors related to worsening renal  
15 function.

16

# 1 **Materials and Methods**

## 2 *Study design and patients*

3 We prospectively studied the changes in renal function after coronary angiography or  
4 contrast-enhanced computed tomography (CT) performed between April 2014 and  
5 March 2017. Patients at risk for CIN, defined as an eGFR <60 mL/min/1.73 m<sup>2</sup> on  
6 coronary angiography or an eGFR <45 mL/min/1.73 m<sup>2</sup> contrast-enhanced CT, were  
7 eligible. The inclusion criterion was age at least 20 years. The exclusion criteria were  
8 as follows: 1) allergy to contrast media, 2) renal replacement therapy, 3) pregnancy, 4)  
9 severe liver dysfunction, and 5) hyperthyroidism. Serum saline loading was performed  
10 at the discretion of the attending physician before and after administration of contrast  
11 media.

12 Pre-study assessments included patient background (age, sex, presence of diabetes,  
13 cardiovascular disease, and smoking), examination conditions (amount of contrast  
14 medium, volume of supplemental fluid), and history of drug use (diuretics, RAS  
15 inhibitors). The blood tests included evaluation of renal function before the contrast

1 test and at 3 days, 1 month, 3 months, 1 year, and 2 years after coronary

2 angiography or contrast-enhanced CT.

3

4 *Variable definitions and study end points*

5 CIN was defined as an increase in serum creatinine level by more than 0.5 mg/dL or

6 a 25% increase from the previous value within 72 hours after iodine contrast

7 administration according to the above guideline [1]. Renal cholesterol crystal

8 embolism was defined as (1) cholesterol crystals on renal biopsy or (2) presence of

9 blue toe and rapidly progressive renal dysfunction, reticular plaques in the lower

10 limbs, or eosinophilia ( $>500/\mu\text{L}$ ).

11 To evaluate the long-term prognosis of renal function after the occurrence of CIN, the

12 primary endpoint was set as worsening renal function, defined as a doubling of

13 serum creatinine or initiation of dialysis at 2 years. The secondary endpoints were the

14 presence of renal cholesterol crystal embolism, death, and an exploratory evaluation

15 of risk factors related to serum creatinine doubling or induction of dialysis at 2 years.

16

1 *Statistical analyses*

2 Our primary analyses were based on assessing the occurrence of CIN and the  
3 associations of CIN with outcomes at 2 years in the overall study population, and  
4 among subgroups by baseline renal function and comorbidities. Th patients were  
5 stratified by comorbidities, and their characteristics were compared using analysis of  
6 variance or chi-square tests for categorical variables. Bonferroni analysis was used  
7 to evaluate the significance of differences among the groups. All statistical analyses  
8 were performed using SPSS statistical software.

9

10 **Results**

11 *Patient characteristics*

12 Of the 162 patients who underwent coronary angiography, 142 patients were  
13 identified to be at risk for CIN and were followed up for 2 years. Meanwhile, of the  
14 283 patients who underwent contrast-enhanced CT examination, 268 were identified  
15 to be at risk for CIN and were followed up for 2 years. Thus, 410 patients were  
16 included in the analysis. Among them, 19 patients (4.6%; 8/142 (5.6%) patients in the

1 coronary angiography group and 11/268 patients in the contrast-enhanced CT group)  
2 developed CIN within 3 days after the administration of contrast media. There were  
3 38/410 (9.3%) patients who had worsening renal function at 2 years. With respect to  
4 the long-term prognosis of CIN, 4/19 (21.1%) patients who developed CIN had  
5 worsening of renal function thereafter (2 and 2 patients in the coronary angiography  
6 and contrast-enhanced CT groups, respectively). The patient characteristics in each  
7 group are detailed below.

8

#### 9 *Coronary angiography group*

10 The mean patient age was 71.6 years, and the mean serum creatinine and eGFR at  
11 the time of enrollment were 1.96 mg/dl and 30.1 ml/min/1.73 m<sup>2</sup>, respectively. There  
12 were 48 patients (33.8%) with diabetes mellitus, and 45 patients (31.7%) received  
13 serum saline infusion before and after the examination. The mean volume of the  
14 contrast medium used was 35 ml (Table 1).

15 The mean serum creatinine level 3 days after angiography was 2.00±0.66 mg/dl,  
16 which was not significantly elevated than that at baseline. After 2 years, 21 patients

1 (14.8%) had serum Cr doubling or initiated dialysis, but only 1 patient developed  
2 cholesterol crystal embolism. Fifteen patients died, and eleven of them died due to  
3 cardiovascular disease (Table 2).

4 Analysis according to renal function at the time of coronary angiography (eGFR  $\geq 30$   
5 ml/min/1.73 m<sup>2</sup> and eGFR of  $\leq 1.73$  m<sup>2</sup>) showed no significant difference in the  
6 occurrence of CIN (Table 3A). There was also no significant association between the  
7 occurrence of CIN and worsening of renal function at 2 years (Table 4A). The factors  
8 related to the worsening of renal function at 2 years were the presence of  
9 cardiovascular disease (i.e., the presence of myocardial infarction, angina pectoris,  
10 and chronic heart failure) and pre-existing renal dysfunction at the time of coronary  
11 angiography (Table 5).

12

### 13 *Contrast-enhanced CT group*

14 The mean patient age was 74.3 years, and the mean serum creatinine and eGFR at  
15 enrollment were 1.72 mg/dl and 35.6 ml/min/1.73 m<sup>2</sup>, respectively. Diabetes mellitus  
16 was present in 76 patients (28.4%), and 47 patients (17.5%) received serum saline

1 infusion before and after the examination. The mean volume of the contrast medium  
2 used was 82 ml (Table 6).

3 The serum creatinine level 3 days after contrast-enhanced CT was  $1.67 \pm 0.58$  mg/dl,  
4 which was not significantly elevated than that at baseline. At 2 years after the  
5 procedure, 17 patients had serum Cr doubling or initiated dialysis, but no patient had  
6 cholesterol crystal embolism. Nineteen patients died, and most deaths were due to  
7 malignancy or infection (Table 2).

8 Analysis by renal function at the time of contrast-enhanced CT (i.e., eGFR  $\geq 30$   
9 ml/min/1.73 m<sup>2</sup> and eGFR  $\leq 1.73$  m<sup>2</sup>) showed no difference in the occurrence of CIN  
10 (Table 3B). There was no significant association between the occurrence of CIN and  
11 the 2-year prognosis of renal function, similar in the coronary angiography group  
12 (Table 4B). The factors associated with the 2-year prognosis of renal function were  
13 age and diabetes mellitus, in addition to pre-existing renal dysfunction (Table 7).

14

## 15 **Discussion**

1 In the past, it was considered that the use of contrast media had a risk of worsening  
2 renal function. However, in the present study, CIN is not a prognostic risk factor for  
3 the long-term of chronic kidney disease after coronary angiography or contrast-  
4 enhanced CT. Pre-existing renal dysfunction is also not a risk factor for CIN, even if  
5 the eGFR is  $<30 \text{ ml/min/1.73 m}^2$ .

6 Contrast-induced acute kidney injury is characterized by a decrease in renal function  
7 that occurs within 3 days after the intravascular administration of an iodinated  
8 contrast material. After contrast media exposure, vasoconstriction leads to intense,  
9 but transient reduction in renal blood flow, direct toxicity to the renal tubular  
10 epithelium, and tubular obstruction by protein precipitates [7]. It is generally believed  
11 that arteriography is associated with a higher risk of contrast-induced acute kidney  
12 injury than venography (e.g., contrast-enhanced CT) owing to the delivery of a more  
13 concentrated contrast material to the kidneys with angiography and the higher overall  
14 risk profile of patients requiring such procedures [8].

15 The 2012 Japanese guidelines on the use of contrast media initially stipulated that a  
16 contrast-enhanced CT scan was associated with a risk of CIN in patients with eGFR

1 <45 ml/min/1.73 m<sup>2</sup>. However, the revised guidelines in 2018 lowered the risk level to  
2 eGFR <30 ml/min/1.73 m<sup>2</sup> [6]. Several studies have also reported that there is no risk  
3 of CIN even in patients with eGFR <30 ml/min/1.73 m<sup>2</sup> [9-12]. Meanwhile, the risk of  
4 CIN remains high in coronary angiography. In this study, the risk of CIN was not  
5 significantly related to renal function at the time of angiography, even in patients with  
6 eGFR <30 ml/min/1.73 m<sup>2</sup>. There was also no risk of CIN in contrast-enhanced CT  
7 scan in patients with eGFR <30 ml/min/1.73 m<sup>2</sup>.

8 Recent studies have suggested that the risk of acute kidney injury due to contrast  
9 material is overestimated [13-17]. The rate of CIN in the present study is lower (5.6%  
10 for arterial contrast and 4.1% for venous contrast) than in previous studies despite  
11 that we included only patients with pre-existing renal dysfunction. Contrast media-  
12 induced renal dysfunction in both coronary angiography and contrast-enhanced CT is  
13 a risk factor for long-term renal dysfunction. However, this study found that the  
14 occurrence of CIN was not significantly related to pre-existing renal dysfunction on  
15 either coronary angiography or contrast-enhanced CT. Furthermore, even if CIN  
16 occurs, it is not associated with the long-term prognosis of renal function. These

1 findings support that there is a reconsideration of “renalism,” in which patients are  
2 discouraged from having contrast studies because of fear of developing CIN, even  
3 though these studies are necessary. However, pre-existing chronic kidney disease is  
4 the strongest patient-related risk factor for long-term renal prognosis, regardless of  
5 the occurrence of CIN.

6 We also found that in coronary angiography, a history of cardiovascular disease was  
7 associated with long-term renal prognosis. Most patients with cardiovascular disease  
8 undergo coronary angiography. Therefore, cardiac function assessment of prior to  
9 coronary angiography is extremely important. In this study, saline administration  
10 before and after angiography or the amount of contrast media used did not lower the  
11 risk of CIN, but this may be due to the small sample size.

12 Only one case of cholesterol crystal embolism was found on coronary angiography in  
13 the current study. Cholesterol crystal embolism causes systemic organ embolism due  
14 to the dissemination of cholesterol crystals caused by the continuous disintegration of  
15 atherosclerotic foci in the walls of large vessels such as the aorta. Thus, it has poor  
16 prognosis. The general population has an approximately 0.06% In probability of

1 cholesterol crystal embolism after cardiac catheterization [18]. The subjects of the  
2 present study were patients with pre-existing renal dysfunction, and the percentage  
3 of occurrence of cholesterol crystal embolism in this study cannot be simply  
4 compared with that of previous reports. A recent approach to coronary angiography  
5 is mainly the radial artery, and the occurrence of cholesterol crystal embolism is  
6 expected to be lower than that in the past. However, when renal function deteriorates  
7 after coronary angiography, it is necessary to pay attention not only to changes in  
8 serum creatinine, but also to the eosinophil count and lower limb symptoms.

9 This study has some limitations. First, the sample size was small, and thus, the study  
10 findings may have limited generalizability. Second, this was a single-center study,  
11 limiting the external validity of the findings. Third, it was not possible to accurately  
12 determine whether the preoperative administration of serum saline was ineffective  
13 because the use of serum saline was randomly assigned by the attending physician's  
14 judgment. A larger clinical study is needed in the future.

15

## 16 **Conclusion**

1 CIN is not a risk factor of long-term renal prognosis after coronary angiography or  
2 contrast-enhanced CT scans. Pre-existing renal dysfunction does not increase the  
3 risk of CIN, even in patients with an eGFR <30 ml/min/1.73 m<sup>2</sup>. These findings will  
4 provide a help that patients with kidney disease who need contrast-enhanced testing  
5 should be tested appropriately.

6

## 7 **Availability of data and materials**

8 The datasets generated and/or analysed during the current study are not publicly  
9 available due to limitations of ethical approval involving the patient data and  
10 anonymity but are available from the corresponding author on reasonable request.

11

## 12 **Abbreviations**

13 **CIN:** Contrast-induced nephropathy

14 **CT:** Computed tomography

15 **eGFR:** estimated glomerular filtration rate

16

## 1 **References**

- 2 1) B J Barrett. Contrast nephrotoxicity. *Am Soc Nephrol.* 1994 Aug;5(2):125-37.
- 3 2) Taliercio CP, Vlietstra RE, Fisher LD, Burnett JC: Risks for renal dysfunction with  
4 cardiac angiography. *Ann Intern Med* 104: 501–504, 1986
- 5 3) Rudnick M, Tumlin J: Pathogenesis, clinical features, and diagnosis of  
6 radiocontrast media-induced acute kidney injury (acute renal failure). In: *Up to*  
7 *Date*, edited by Rose BD, UpToDate, Waltham, MA, 2007
- 8 4) Manske CL, Sprafka JM, Strony JT, Wang Y: Contrast nephropathy in azotemic  
9 diabetic patients undergoing coronary angiography. *Am J Med* 89: 615–620, 1990
- 10 5) Barrett BJ, Parfrey PS, Vavasour HM, McDonald J, Kent G, Hefferton D, O’Dea F,  
11 Stone E, Reddy R, McManamon PJ: Contrast nephropathy in patients with  
12 impaired renal function: high versus low osmolar media. *Kidney Int* 41:1274 –  
13 1279, 1992
- 14 6) Isaka Y, Hayashi H, Aonuma K, Horio M, Terada Y, Doi K, Fujigaki Y, Yasuda H,  
15 Sato T, Fujikura T, Kuwatsuru R, Toei H, Murakami R, Saito Y, Hirayama A,  
16 Murohara T, Sato A, Ishii H, Takayama T, Watanabe M, Awai K, Oda S,

- 1 Murakami T, Yagyu Y, Joki N, Komatsu Y, Miyauchi T, Ito Y, Miyazawa R, Kanno  
2 Y, Ogawa T, Hayashi H, Koshi E, Kosugi T, Yasuda Y; Japanese Society of  
3 Nephrology, Japan Radiological Society, and Japanese Circulation Society Joint  
4 Working Group. Guideline on the use of iodinated contrast media in patients with  
5 kidney disease 2018. Clin Exp Nephrol. 2020 Jan;24(1):1-44.
- 6 7) Gruberg L, Mintz GS, Mehran R, Gangas G, Lansky AJ, Kent KM, Pichard AD,  
7 Satler AF, Leon MB. The prognostic implications of further renal function  
8 deterioration within 48 h of interventional coronary procedures in patients with pre-  
9 existent chronic renal insufficiency. J Am Coll Cardiol. 2000 Nov 1;36(5):1542-8.
- 10 8) Roxana Mehran, George D Dangas, Steven D Weisbord. Contrast-Associated  
11 Acute Kidney Injury. N Engl J Med. 2019 May 30;380(22):2146-2155
- 12 9) McDonald JS, McDonald RJ, Carter RE, KatBerg RW, Kallmes DF, Williamson  
13 EE. Risk of intravenous contrast material-mediated acute kidney injury: a  
14 propensity score-matched study stratified by baseline-estimated glomerular  
15 filtration rate. Radiology 2014; 271: 65-73

- 1 10) Jeremiah S Hinson, Michael R Ehmann, Derek M Fine, Elliot K Fishman,  
2 Matthew F Toerper, Richard E Rothman, Eili Y Klein. Risk of Acute Kidney Injury  
3 After Intravenous Contrast Media Administration. *Ann Emerg Med.* 2017  
4 May;69(5):577-586.e4.
- 5 11) Jennifer S McDonald, Robert J McDonald, Eric E Williamson, David F Kallmes. Is  
6 Intravenous Administration of Iodixanol Associated with Increased Risk of Acute  
7 Kidney Injury, Dialysis, or Mortality? A Propensity Score-adjusted Study.  
8 *Radiology.* 2017 Nov;285(2):414-424.
- 9 12) Shu Min Tao, Xiang Kong, U Joseph Schoepf, Julian L Wichmann, Darby C  
10 Shuler, Chang Sheng Zhou, Guang Ming Lu, Long Jiang Zhang. Acute kidney  
11 injury in patients with nephrotic syndrome undergoing contrast-enhanced CT for  
12 suspected venous thromboembolism: a propensity score-matched retrospective  
13 cohort study. *Eur Radiol* 2018 Apr;28(4):1585-1593.
- 14 13) McDonald JS, Leake CB, McDonald RJ, et al. Acute kidney injury after  
15 intravenous versus intra-arterial contrast material administration in a paired cohort.  
16 *Invest Radiol* 2016; 51: 804-9.

- 1 14) McDonald RJ, McDonald JS, Bida JP, et al. Intravenous contrast material-  
2 induced nephropathy: causal or coincident phenomenon? Radiology 2013; 267:  
3 106-18.
- 4 15) McDonald RJ, McDonald JS, Carter RE, et al. Intravenous contrast material  
5 exposure is not an independent risk factor for dialysis or mortality. Radiology 2014;  
6 273:714-25.
- 7 16) Bruce RJ, Djamali A, Shinki K, Michel SJ, Fine JP, Pozniak MA. Background  
8 fluctuation of kidney function versus contrast- induced nephrotoxicity. AJR Am J  
9 Roentgenol 2009;192:711-8.
- 10 17) Goulden R, Rowe BH, Abrahamowicz M, Strumpf E, Tamblyn R. Association of  
11 Intravenous Radiocontrast With Kidney Function: A Regression Discontinuity  
12 Analysis. JAMA Intern Med. 2021 Apr 5:e210916.
- 13 18) Johnson LW, Esente P, Giambartolomei A, et al: Peripheral vascular  
14 complications of coronary angioplasty by the femoral and brachial techniques.  
15 Cathet Cardiovasc Diagn 3: 165-172, 1994  
16

1 **Acknowledgement**

2 We would like to thank Editage ([www.editage.com](http://www.editage.com)) for English language editing.

3

4 **Funding**

5 None

6

7 **Author information**

8 Affiliations

9 **1. Kidney Disease and Transplant Center, Shonan Kamakura General Hospital,**

10 **1370-1, Okamoto, Kamakura, Kanagawa, 247-8533, Japan**

11 Hidekazu Moriya, Yasuhiro Mochida, Kunihiro Ishioka, Machiko Oka, Kyoko

12 Maesato, Mizuki Yamano, Hiroyuki Suzuki, Takayasu Ohtake, Sumi Hidaka, and

13 Shuzo Kobayashi

14 Contributions

15 HM, YM, KI, MO, KM, MY, HS, TO, SH collected data. HM analyzed data and wrote

16 the manuscript. HM and SK designed the study and critically reviewed the

1 manuscript. All authors reviewed the manuscript. The author(s) read and approved  
2 the final manuscript.

3 Corresponding author

4 Correspondence to Hidekazu Moriya

5

## 6 **Ethics declarations**

7 Ethics approval and consent to participate

8 This study was approved by the Tokushukai Group Ethics Committee (Registration

9 number: TGE00389-024) and was conducted according to the tenets of the Helsinki

10 Declaration. Informed consent was obtained from all patients.

11

## 12 **Consent for publication**

13 Not applicable.

14

## 15 **Competing interests**

16 The authors report no conflicts of interest.

17

1 **Tables**

2

3 Table 1. Patient characteristics in the coronary angiography group (n=142)

4

---

Age (years)	71.6±12.1
Sex (M/F)	119/43
Smoking	34 (23.9)
Diabetes	48 (33.8)
Cardiovascular disease	56 (39.4)
Systolic blood pressure (mmHg)	123±14
Diastolic blood pressure (mmHg)	78±8
Blood urea nitrogen (mg/dl)	28.6±5.6
Creatinine (mg/dl)	1.96±0.71
Estimated glomerular filtration rate (ml/min/1.73m <sup>2</sup> )	30.1±11.3
Albumin (g/dl)	3.4±0.4
Hemoglobin (g/dl)	13.4±2.3
Eosinophil count (/μl)	234±22
Saline infusion	45 (31.7)
Volume of saline infused (ml)	845±235
Volume of contrast media administered (ml)	35±22

---

5 Data are presented as the mean or n (%).

6

1 Table 2. Changes in serum creatinine and outcomes at 2 years in patients  
 2 undergoing coronary angiography or contrast-enhanced computed tomography  
 3

	Serum creatinine (mg/dl)						CIN (n(%))	CCE (n(%))	Worsening of renal function (n(%))	Death (n/(%))
	baseline	3 days	1 month	3 months	1 year	2 years				
Angiography (n=142)	1.96 ± 0.71	2.00 ± 0.66	1.84 ± 0.52	1.89 ± 0.59	2.38 ± 1.26	2.58 ± 1.30	8 (5.6)	1 (0.7)	21 (14.8)	15 (10.6)
CT (n=268)	1.72 ± 0.74	1.67 ± 0.58	1.36 ± 0.55	1.38 ± 0.54	1.69 ± 0.60	1.98 ± 0.95	11 (4.1)	0 (0.0)	17 (6.3)	19 (7.1)

4  
 5 Abbreviations: CT, computed tomography; CIN, contrast-induced nephropathy; CCE,  
 6 cholesterol crystal embolism;  
 7

1 Table 3. Relationship between the occurrence of CIN and renal function at contrast  
 2 media administration

3

4 A. Coronary angiography

n=142	Renal function at contrast media administration		<i>p</i>
	(estimated glomerular filtration rate [eGFR])		
	$\geq 30$ ml/min/1.73m <sup>2</sup>	<30 ml/min/1.73m <sup>2</sup>	
Contrast-induced nephropathy (CIN) (+)	3 (2.1%)	5 (3.5%)	0.441
CIN (-)	69 (48.6%)	65 (45.8%)	

5

6 B. Contrast-enhanced computed tomography

n=268	Renal function at contrast media administration		<i>p</i>
	(eGFR)		
	$\geq 30$ ml/min/1.73m <sup>2</sup>	<30 ml/min/1.73m <sup>2</sup>	
CIN (+)	5 (1.9%)	6 (2.2%)	0.457
CIN (-)	146 (54.5%)	111 (41.4%)	

7

8

1 Table 4. Relationship between occurrence of contrast-induced nephropathy and  
 2 worsening of renal function at 2 years

3

4 A. Coronary angiography

n=142	Worsening of renal function		<i>p</i>
	(+)	(-)	
Contrast-induced nephropathy (CIN) (+)	2 (1.4%)	6 (4.2%)	0.402
CIN (-)	19 (13.4%)	115 (81.0%)	

5

6 B. Contrast-enhanced computed tomography

n=268	Worsening of renal function		<i>p</i>
	(+)	(-)	
CIN (+)	2 (0.7%)	9 (3.4%)	0.099
CIN (-)	15 (5.6%)	242 (90.4%)	

7

8

9

10

1 Table 5. Factors associated with worsening renal function after coronary angiography  
 2 (n=142)

3

		Number	Worsened renal function (n, %)	<i>p</i>
Diabetes	(-)	94	9 (9.6)	0.089
	(+)	48	12 (25.0)	
Cardiovascular disease	(-)	86	4 (4.7)	<0.001
	(+)	56	17 (30.4)	
Diuretics	(-)	114	15 (13.2)	0.269
	(+)	28	6 (21.4)	
Renin angiotensin system inhibitors	(-)	54	9 (16.7)	0.621
	(+)	88	12 (13.6)	
Serum creatinine (mg/dl)	-1.5	78	1 (1.3)	<0.001
	1.5-2.5	42	8 (19.4)	
	2.5-	22	12 (54.5)	
Estimated glomerular filtration rate (ml/min/1.73m <sup>2</sup> )	45-	34	1 (2.9)	<0.001
	30-45	66	6 (9.1)	
	-30	42	14 (33.3)	
Age	80-	34	9 (26.5)	0.053
	60-80	78	7 (9.0)	
	-60	30	5 (16.7)	
Volume of contrast media administered (ml)	-25	78	9 (11.5)	0.112
	25-50	44	6 (13.6)	
	50-	20	6 (30.0%)	
Saline infusion	(-)	97	15 (15.5)	0.739
	(+)	45	6 (13.3)	

4 †, *p* <0.001; ‡, *p* <0.01

5

1 Table 6. Patient characteristics in the contrast-enhanced computed tomography  
2 group (n=268)

3

---

Age (years)	74.3±11.1
Sex (M/F)	177/109
Smoking	48(17.9)
Diabetes	76(28.4%)
Cardiovascular disease	42(15.7)
Systolic blood pressure (mmHg)	132±12
Diastolic blood pressure (mmHg)	82±8
Blood urea nitrogen (mg/dl)	20.5±5.6
creatinine (mg/dl)	1.72±0.74
Estimated glomerular filtration rate (ml/min/1.73m <sup>2</sup> )	35.6±8.8
Albumin (g/dl)	3.3±0.4
Hemoglobin (g/dl)	11.8±1.8
Eosinophil count (/μl)	379±65
Saline infusion (n(%))	47(17.5)
Volume of saline infused (ml)	568±40
Volume of contrast media administered (ml)	82±34

---

4 Data are presented as the mean or n (%).

5

6

1 Table 7. Factors correlated with renal function deterioration in the contrast-enhanced  
 2 CT group (n=268)

3

		Number (n)	Worsening renal function, n (%)	<i>p</i>
Diabetes	(-)	192	7 (3.6)	<0.001
	(+)	76	10 (13.2)	
Cardiovascular disease	(-)	226	11 (4.7)	0.125
	(+)	42	6 (14.3)	
Diuretics	(-)	234	13 (5.6)	0.127
	(+)	34	4 (11.8)	
Renin angiotensin system inhibitor	(-)	192	11 (5.7)	0.529
	(+)	76	6 (7.9)	
Serum creatinine (mg/dl)	-1.5	186	0 (0.0)	] † ] + <0.001
	1.5-2.5	55	8 (14.5)	
	2.5-	27	9 (33.3)	
Estimated glomerular filtration rate (ml/min/1.73m <sup>2</sup> )	30-45	211	6 (2.8)	<0.001
	-30	57	11 (19.3)	
Age	-80	34	7 (20.6)	] ‡ ] * 0.002
	60-80	176	7 (4.0)	
	60-	58	3 (5.2)	
Volume of contrast media administered (ml)	-50	16	2 (12.5)	0.132
	50-100	212	10 (4.7)	
	100-	40	5 (12.5)	
Saline infusion	(-)	221	13 (5.9)	0.56
	(+)	47	4 (8.5)	

4 †, *p*<0.001; ‡, *p*<0.01; \*, *p*<0.05

5